- Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with ...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the third quarter ended September 27, ...
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustai...
-Corventum, Inc., a new medicines company advancing novel therapies to make existing cancer treatments safer and more effective, announced the clea...
Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the...
Industry report measures progress in six main areas: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government polic...
CRYPTICS study met the primary efficacy endpoint measure, 24-hour chest tube drainage (Difference in LS Means was 142.0 mL; 95.576% confidence interval...
New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips deb...
Pierre Boulud, Chief Executive Officer of bioMérieux, set the tone for the company’s first-half 2025 performance: “With a stron...
NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two years NPI-001 was well tolerated, with no persiste...
-Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, announced results from the landmark myCare-040 clinical ...
Corner Therapeutics, an in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection, published research in mB...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 2...
© 2025 Biopharma Boardroom. All Rights Reserved.
